Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > So what now?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(93)
•••
Comment by MasterAlgaeon Aug 03, 2021 9:39am
264 Views
Post# 33641682

RE:So what now?

RE:So what now?The drug is highly toxic to some people for sure.
What were the actual liver transaminase levels for each participant? We need to know that. Does everyone who takes the drug get elevated liver transaminase?
What happens after 38 days of taking the drug, what happens after 6 months or a year?
There are drugs that are like that and people are monitored for the toxicity. Methotrexate for instance which was originally a cancer drug and an is an immunosupressant.
The rosey view of market share though just got reaistic.
Antibe has only one product Hydrogen Sulphide it throws a shadow over the entire pipeline and the future of the company.
Partnership and NASDAQ listing...?
Timelines?


Forestview wrote: They stock will take a massive hit.  But, ATE isn't going to close up shop.  What are the next steps, anyone been through this?  Will the AME pick back up again?  Is P3 still going to happen? What happens to the pipeline?  Would appreciate some rational views...


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities